These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18824704)

  • 21. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 22. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Chang DZ; Abbruzzese JL
    Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
    [No Abstract]   [Full Text] [Related]  

  • 23. Developments in combination chemotherapy for colorectal cancer.
    Goetz MP; Grothey A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):627-37. PubMed ID: 15270666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unresectable hepatic colorectal metastases: need for new surgical strategies.
    Vauthey JN; Abdalla EK
    Ann Surg Oncol; 2006 Jan; 13(1):5-6. PubMed ID: 16372151
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?
    Rothenberg ML; Berlin JD
    J Clin Oncol; 2003 Oct; 21(20):3716-7. PubMed ID: 12963700
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advances in palliative and adjuvant chemotherapy of colon cancer].
    Scheithauer W
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2118-21. PubMed ID: 15455304
    [No Abstract]   [Full Text] [Related]  

  • 27. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 28. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 29. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
    Hwang JJ
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
    Sato T; Kokuba Y; Ozawa H; Hatate K; Nakamura T; Onosato W; Ihara A; Watanabe M
    Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():257-9. PubMed ID: 17469353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential chemotherapy for colorectal cancer.
    Seymour M
    Lancet Oncol; 2011 Oct; 12(11):987-8. PubMed ID: 21903471
    [No Abstract]   [Full Text] [Related]  

  • 34. [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
    Motomura S
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():360-3. PubMed ID: 14574913
    [No Abstract]   [Full Text] [Related]  

  • 35. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
    Ledermann JA; Leonard P; Seymour M
    N Engl J Med; 2001 Jul; 345(2):145-6. PubMed ID: 11450667
    [No Abstract]   [Full Text] [Related]  

  • 36. [Surgery and chemotherapy for colorectal cancer: current status and perspective].
    Kawamura Y; Konishi F
    Nihon Shokakibyo Gakkai Zasshi; 2007 Jul; 104(7):1018-24. PubMed ID: 17611378
    [No Abstract]   [Full Text] [Related]  

  • 37. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chemotherapy for elderly patients with colorectal cancer].
    Kuboki Y; Mizunuma N
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):380-6. PubMed ID: 17353628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
    Krieger G
    Strahlenther Onkol; 2001 Jun; 177(6):316-8. PubMed ID: 11446323
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
    Bao HY; Fang WJ; Zhang XC; Shi GM; Huang S; Yu LF; Chen J; Mou HB; Deng J; Shen P; Xu N
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):147-52. PubMed ID: 20221830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.